Seizures clinical trials at UC Irvine

1 research study open to eligible people

XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
open to eligible people ages 18 years and up
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Orange, California and other locations

Last updated: September 7, 2023